Balanced news tone
News Sentiment
IMRN sentiment intelligence
Immuron Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
42 relevant articles
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+11.8% over one week, +3.4% over four weeks, trend active, and below fair value.
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
80/100 classification
One-week reaction
11.8%
Price confirming higher
Trend fit
Trend active
3.4% over four weeks
Fair value
-32.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
24
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
GlobeNewswire
Direct company coverage
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 16 Jul 2026 10:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Immuron's Travelan Sales Grow for Four Straight Quarters
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 10:00
- Source
- Stock Titan
grafa.com
Direct company coverage
Australia's Immuron sales reach $7.7 million in FY26
Immuron (ASX:IMC) announced global sales of $7.7 million for FY26, marking a 6% increase over the previous year. This growth was primarily driven by strong sales of Travelan in Australia and steady expansion in North America. Despite the positive sales figures, the Immuron share
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 16 Jul 2026 02:30
- Source
- grafa.com
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
MT Newswires
Direct company coverage
Immuron Seeking Partner to Advance IMM-529 in Clostridioides Difficile Infection
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 11:01
- Source
- MT Newswires
Stock Titan
Direct company coverage
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push
Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for its IMM-529 program, which targets Clostridioides difficile infection (CDI). IMM-529 has FDA Investigational New Drug approval for a planned Phase 2 trial in Australia, with a projected base case
- Tone
- Positive 73/100
- Event
- Regulatory and legal
- Published
- 06 Jul 2026 11:40
- Source
- Stock Titan
Kalkine
Direct company coverage
Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy
Immuron Limited has engaged Pullan Consulting to strategically advance its investigational drug, IMM-529, designed to treat Clostridioides difficile infection (CDI). This move follows the FDA's approval of IMM-529's Investigational New Drug (IND) application, allowing for upcomin
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 06 Jul 2026 10:53
- Source
- Kalkine
markets.businessinsider.com
Direct company coverage
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Immuron Limited has engaged Pullan Consulting to advance its partnering strategy for IMM-529, a treatment for Clostridioides difficile infection (CDI). The company has FDA approval for its IMM-529 Investigational New Drug application and is seeking a partner to fund clinical deve
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 06 Jul 2026 10:40
- Source
- markets.businessinsider.com
Stock Titan
Direct company coverage
Immuron seeks partner for gut infection drug IMM-529
Immuron (NASDAQ: IMRN, ASX: IMC) has engaged Pullan Consulting to find a strategic partner for IMM-529, its oral polyclonal antibody candidate for Clostridioides difficile infection (CDI). IMM-529 has FDA-cleared IND 32095 and is Phase 2 trial-ready, with a planned randomized, do
- Tone
- Positive 76/100
- Event
- Market update
- Published
- 06 Jul 2026 09:40
- Source
- Stock Titan
dars.gov.et
Direct company coverage
Immuron (IMRN) Edges Higher Amid Low-Volume Trading; Potential Consolidation Near Support - ADD Alert
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Jul 2026 02:31
- Source
- dars.gov.et
Stock Titan
Direct company coverage
Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue
Immuron Limited (NASDAQ: IMRN) has announced a change in its issued capital, with 3,805,528 ordinary fully paid shares ceasing on the ASX. Following this cessation, the company now has 322,848,081 ordinary shares on issue. This adjustment to the share count will be used by the AS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 11:59
- Source
- Stock Titan
Kalkine
Direct company coverage
Immuron Cancels 3.8 Million Shares at $0.032 Each Under Unmarketable Parcel Buy-Back
Immuron Limited (ASX: IMC) has completed the cancellation of 3,805,528 ordinary fully paid shares at AUD $0.032 each as part of an unmarketable parcel buy-back program, effective June 29, 2026. This move reduces the company's total quoted ordinary share count to 322,848,081 and a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 02:41
- Source
- Kalkine
Investing.com India
Direct company coverage
Form 6K Immuron Ltd ADR For: 23 June By Investing.com
This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23rd. The content itself is very brief, consisting only of the headline repeated several times, and primarily serves as an entry point to Investing.com's broader financial news and market data platform, wit
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 27 Jun 2026 04:40
- Source
- Investing.com India
Investing.com
Direct company coverage
Form 6K Immuron Ltd ADR For: 23 June
This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23. It also includes standard disclaimers about the risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility and potential loss of investment. The content stresse
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 13:10
- Source
- Investing.com
Stock Titan
Direct company coverage
Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back
Immuron Limited has completed a small holding share sale facility, buying back 3,805,528 ordinary shares at $0.032 per share, totaling $121,777. These shares will be cancelled, reducing the company's total shares on issue from 326,653,609 to 322,848,081 and decreasing the number
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 22:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital
Immuron Limited announced the expiry of 1.43 million IMCAI options listed on the ASX, which ceased on June 18, 2026, without being exercised or converted, and with no consideration paid. Following this, the company updated its issued capital to 326,653,609 ordinary fully paid sha
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 21:40
- Source
- Stock Titan
TradingKey
Direct company coverage
Immuron Ltd (IMRN) Institutional Confidence
This article from TradingKey provides an overview of institutional confidence in Immuron Ltd (IMRN). It lists specific institutional shareholders, their shareholdings, and the percentage change in their positions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisor
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jun 2026 20:39
- Source
- TradingKey
TradingKey
Direct company coverage
Immuron Ltd (IMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Immuron Ltd (IMRN), detailing support and resistance levels, and analyzing various technical indicators and moving averages. As of the report, IMRN's technical indicators present a mixed signal with 1 buy and 2 sell signals, while mov
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 17 Jun 2026 10:10
- Source
- TradingKey
TradingKey
Direct company coverage
Immuron Ltd (IMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Immuron Ltd (IMRN), highlighting that one analyst rates the stock as a "Buy" with a target price of USD 5.00, representing a potential upside of 257.14%. The company's current stock price is 1.040 USD, with a market cap of 7.56M. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 07:40
- Source
- TradingKey
TradingKey
Direct company coverage
Immuron Ltd (IMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Immuron Ltd (IMRN)'s dividend and stock split history. It indicates that no dividends have been distributed in the past five years and there is no data available for past stock splits. The page serves as a data placeholder for these financial
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 05:11
- Source
- TradingKey
TradingKey
Direct company coverage
Immuron Ltd (IMRN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Immuron Ltd (IMRN), listing its major shareholders and institutional holdings as of recent reporting periods. Key institutional investors include Morgan Stanley, Citadel Advisors, and XTX Markets, with updated statistics on shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 05:11
- Source
- TradingKey
TradingKey
Direct company coverage
Immuron Ltd (IMRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Immuron Ltd (IMRN) as of July 6, 2023, showcasing its performance across different business segments and geographical regions. It highlights that the Travelan segment accounts for the vast majority of its revenue at 96.68%, w
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 04:11
- Source
- TradingKey
Kalkine Media
Direct company coverage
Immuron (ASX: IMC): Advancing Gastrointestinal Product Portfolio Across Multiple Markets
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is actively expanding its gastrointestinal product portfolio and market presence, focusing on digestive health with products like Travelan® for travellers' diarrhoea and ProIBS® for IBS symptoms. The company reported a 16% increase in globa
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 02 Jun 2026 04:09
- Source
- Kalkine Media
Finviz
Direct company coverage
IMRN - Immuron Limited ADR Stock Price and Quote
This article provides a detailed stock quote and company information for Immuron Limited (IMRN), an Australian biopharmaceutical company. It includes financial data, performance metrics, key ratios, and a comprehensive list of recent company news and events. The company focuses o
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 May 2026 13:12
- Source
- Finviz
Stock Titan
Direct company coverage
Immuron (NASDAQ: IMRN) responds to ASX query on share price
Immuron Limited has filed a Form 6-K in response to an ASX price query regarding recent trading activity in its shares. The company stated it is not aware of any undisclosed information that would explain the movements and confirmed its compliance with ASX Listing Rule 3.1 on con
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 12:08
- Source
- Stock Titan
ChartMill
Direct company coverage
IMRN Technical Analysis | Trend, Signals & Chart Patterns | IMMURON LTD-SPON ADR (NASDAQ:IMRN)
IMMURON LTD-SPON ADR (IMRN) has a strong technical rating of 8 out of 10, showing positive short-term trends and outperforming 85% of all stocks in the past year. However, its setup rating is low at 1 due to extended recent price rises, suggesting a wait for consolidation before
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 May 2026 11:39
- Source
- ChartMill
Moomoo
Direct company coverage
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
Emerging Growth Research has released a Flash Report on Immuron (Nasdaq: IMRN), reaffirming its Buy-Extended rating and elevating its 12-month price target from $3.90 to $4.00. This increase reflects Immuron's continued revenue growth, expanding commercial presence, and advanceme
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 23 May 2026 10:40
- Source
- Moomoo
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3
Immuron Ltd Chief Commercial Officer Flavio Palumbo has filed an initial ownership report (Form 3) disclosing his equity interests in the company. The filing indicates he directly holds 1,142,909 Ordinary Shares and 640,824 Performance Rights. These Performance Rights have a zero
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immuron (IMRN) director discloses shareholdings and long-dated options
Immuron Ltd director Daniel Jude Pollock has filed an initial Form 3, disclosing his direct ownership of 568,750 Ordinary Shares and indirect ownership of 174,480 Ordinary Shares through joint ownership with his spouse. The filing also reveals his holdings of options over 1,000,0
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 20:10
- Source
- Stock Titan